Business Context and Reporting Period
This Form 8-K, dated December 14, 2005, reports material definitive agreements entered into by Xcyte Therapies, Inc. (a Delaware corporation). The filing details a proposed reverse merger with Cyclacel Group plc and a concurrent asset sale to Invitrogen Corporation. Upon completion, Xcyte will change its name to Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Values
- Asset Sale Proceeds: Xcyte agreed to sell its T cell expansion technology ("Xcellerate Process") to Invitrogen Corporation for $5 million.
- Price Adjustment: The $5 million purchase price is subject to a post-closing adjustment requiring Xcyte to refund up to $1 million to Invitrogen.
- Equity Structure: In the merger with Cyclacel, Xcyte will issue shares representing approximately 80% of its outstanding common stock to Cyclacel.
- Termination Fees: Both the Stock Purchase Agreement and Asset Purchase Agreement include provisions for a termination fee of $100,000 payable by either party under specified circumstances.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes and Transaction Details
The filing announces two simultaneous material changes to the company's operations and capital structure:
- Reverse Merger: Xcyte will acquire all capital stock of Cyclacel Ltd. (a subsidiary of Cyclacel Group plc). Following the share issuance, Cyclacel will initiate a voluntary liquidation to distribute Xcyte shares to its own stockholders. Xcyte will rename itself Cyclacel Pharmaceuticals, Inc.
- Asset Divestiture: Xcyte will divest its core T cell expansion technology, including intellectual property, clinical data from six trials, raw materials, and equipment, to Invitrogen.
Guidance, Risks, and Contingencies
Conditions Precedent: Both transactions are subject to customary conditions, including stockholder approval from both Xcyte and Cyclacel, absence of legal prohibitions, and the accuracy of representations and warranties.
Risks and Uncertainties: The filing highlights significant risks that could prevent the transactions from closing, including:
- Failure to obtain stockholder approval.
- Failure to obtain required regulatory approvals.
- Delays in closing or failure to consummate the transaction.
- Non-payment of the purchase price.
Management Commentary: Management has entered into voting agreements with certain stockholders to support the transactions. A proxy statement/prospectus on Form S-4 will be filed to solicit stockholder approval.
Investor Verification Checklist
- Verify the final terms of the $5 million asset sale and the potential $1 million refund obligation to Invitrogen.
- Confirm the outcome of the stockholder votes required for both the Cyclacel merger and the Invitrogen asset sale.
- Review the upcoming Form S-4 proxy statement/prospectus for details on the post-transaction capital structure and director interests.
- Assess the impact of divesting the "Xcellerate Process" on the company's future business model and revenue generation.
- Monitor for any regulatory approvals required for the name change and the reverse merger structure.